As part of the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research (CDER) grants approval to new drugs or biologics in a variety of therapeutic areas every year. These products contain ingredients that have not been previously approved by the FDA and are important new therapies for patient populations in their respective areas.

By December 30, 2022, 37 drugs were approved by the FDA, covering a wide range of diseases including cancer, diabetes, blood disorders, autoimmune diseases, infections, and rare diseases. The following is a compilation of the top 10 FDA-approved drugs and biologics in various therapy areas selected by GeneOnline, with a review of key clinical data and mechanism of action (MOA), hoping to help readers to predict the development trend in 2023 by looking at novel drug approvals for 2022.